Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) EBIT Margin (2019 - 2026)

C4 Therapeutics has reported EBIT Margin over the past 8 years, most recently at 451.64% for Q1 2026.

  • For Q1 2026, EBIT Margin fell 4871.0% year-over-year to 451.64%; the TTM value through Mar 2026 reached 326.56%, down 3358.0%, while the annual FY2025 figure was 320.53%, 1561.0% up from the prior year.
  • EBIT Margin for Q1 2026 was 451.64% at C4 Therapeutics, down from 210.1% in the prior quarter.
  • Over five years, EBIT Margin peaked at 178.59% in Q2 2024 and troughed at 1410.21% in Q2 2023.
  • A 5-year average of 598.03% and a median of 440.99% in 2025 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: plummeted -126575bps in 2022 and later soared 123162bps in 2024.
  • Year by year, EBIT Margin stood at 1341.73% in 2022, then rose by 14bps to 1147.72% in 2023, then soared by 37bps to 728.39% in 2024, then skyrocketed by 71bps to 210.1% in 2025, then tumbled by -115bps to 451.64% in 2026.
  • Business Quant data shows EBIT Margin for CCCC at 451.64% in Q1 2026, 210.1% in Q4 2025, and 306.43% in Q3 2025.